# Neuromodulation for Metabolic Dysfunction

Study · id `cardio:ct-nct07597161` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07597161](<https://clinicaltrials.gov/study/NCT07597161>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07597161

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT07597161. Randomized; single masking; primary purpose other. Start 2026-10-20 (actual); primary completion 2030-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose other
- Phase: Not applicable
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT07597161, source copy `cardio:ctgov-nct07597161-2026-10-29`, retrieved 2026-10-31)
- Started: 2026-10-20 (actual) (ClinicalTrials.gov record NCT07597161, source copy `cardio:ctgov-nct07597161-2026-10-29`, retrieved 2026-10-31)
- Primary completion: 2030-05-31 (anticipated) (ClinicalTrials.gov record NCT07597161, source copy `cardio:ctgov-nct07597161-2026-10-29`, retrieved 2026-10-31)
- Completion: 2030-12 (anticipated) (ClinicalTrials.gov record NCT07597161, source copy `cardio:ctgov-nct07597161-2026-10-29`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT07597161, source copy `cardio:ctgov-nct07597161-2026-10-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07597161-2026-10-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Neuromodulation for Metabolic Dysfunction
- Condition: Spinal Cord Injuries (SCI)
- Condition: Prediabetes / Type 2 Diabetes
- Intervention (Device): Transcutaneous Spinal Cord Stimulation (tSCS)
- Intervention (Device): Sham transcutaneous spinal cord stimulation (tSCS)
- Lead sponsor: Rahul Sachdeva
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: e66edfeebb5b3142fa3bdd91464ce963c0528211543e3ba31152884ef704b7e5
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
